About Upadacitinib API
Therapeutic CategoryImmunology
CAS Number
1310726‑60‑3
API Technology
Small‑molecule synthetic API
Dose Form
Tablets
Dr Reddy's Development Status
Under Development
Mechanism of action
Upadacitinib selectively inhibits JAK1, a key intracellular tyrosine kinase involved in the JAK‑STAT signaling pathway.
By blocking JAK1, upadacitinib:
Prevents phosphorylation and activation of STAT transcription factors
Inhibits signaling from multiple pro‑inflammatory cytokines (e.g., IL‑6, IL‑2, IL‑12, IL‑23, interferons)
Indication
Approved indications (FDA / EMA):
Rheumatoid arthritis (moderate to severe)
Psoriatic arthritis
Ankylosing spondylitis
Non‑radiographic axial spondyloarthritis
Atopic dermatitis (moderate to severe)
Ulcerative colitis
Crohn’s disease
Giant cell arteritis
Polyarticular juvenile idiopathic arthritis
Related APIs
Upadacitinib
Immunology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.